Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA®- More than 1,000 new patient enrollments for YORVIPATH in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results